CuraSen Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
930 Brittan Ave 306, San Carlos, Califor...Phone Number
(650) 475-2842Website
www.curasen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About CuraSen Therapeutics
CuraSen Therapeutics, Inc. is focused on rethinking brain disease through innovative scientific approaches. The company is engaged in developing therapies aimed at addressing various neurological conditions. Their intended clients include patients suffering from brain diseases and healthcare providers seeking advanced treatment options. CuraSen is committed to advancing its pipeline of therapeutic solutions to improve patient outcomes.Explore more
CuraSen Therapeutics Org Chart
JR
Senior Director, Clinical Operations
RM
Associate Director, Translational Science
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CuraSen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CuraSen Therapeutics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CuraSen Therapeutics launches new products
Funding: Get notified immidiatlly once CuraSen Therapeutics has new funding data
CuraSen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on CuraSen Therapeutics recently announced quarterly report
Check out if CuraSen Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at CuraSen Therapeutics
Website visits: Recent activity has been detected on your website
Check if CuraSen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at CuraSen Therapeutics
Find more new buyers
Compare Similar Companies to CuraSen Therapeutics
Compare insights from companies similar to CuraSen Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CuraSen Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CuraSen Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CuraSen Therapeutics.
CuraSen Therapeutics financials insights
Gather financial insights about CuraSen Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$5.8M
CuraSen Therapeutics Tech Stack
A closer look at the technologies used by CuraSen Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Executive Move
Executive Moves, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Funding
CuraSen Therapeutics News & Media
CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer
SAN CARLOS, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oral, rapid onset, small molecule drugs to treat psychiatric and neurodegenerative diseases, announced today that it has appointed Kathleen Sereda Glaub, MBA, formerly executive chair, as chief executive officer. Dr. Anthony Ford will move to the role of president and chief scientific officer, and continue to lead research and development. Patrick Enright, managing director ofCuraSen Therapeutics Announces Oral Presentation of Additional Positive Phase 2a Data with CST-2032/CST-107 in Patients with Alzheimer’s or Parkinson’s Disease at AD/PD™ 2024 International Conference
SAN CARLOS, Calif. & LISBON, Portugal--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it will present additional positive Phase 2a data with its combination adrenergic activator, CST-2032/CST-107, in patients with mild cognitive impairment (MCI) or mild dementia from either Alzheimer’s or Parkinson’s disease. The oral presentation will take place at AD/PD™ 2024: The International ConferCuraSen Therapeutics Receives Up To $5.8M Investment from Alzheimer’s Drug Discovery Foundation
CuraSen Therapeutics, a San Carlos, CA-based clinical-stage company developing small molecule therapies to treat neurodegenerative disease, received up to $5.8M in investment from Alzheimer’s Drug Discovery Foundation (ADDF). The company intends to use the funds to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease. Led by CEO Anthony Ford, CuraSen […] The post CuraSen Therapeutics Receives Up To $5.8M Investment from Alzheimer’s Drug Discovery FCuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease
SAN MATEO, Calif.--(BUSINESS WIRE)--CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an alpha-1A adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease. “We are thrilled to receive this investment from the Alzheimer’s Drug Discovery Foundation which will b
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CuraSen Therapeutics
Sign Up For FreeTo access detailed company insights
CuraSen Therapeutics, Inc. is focused on rethinking brain disease through innovative scientific approaches. The company is engaged in developing therapies aimed at addressing various neurological conditions. Their intended clients include patients suffering from brain diseases and healthcare providers seeking advanced treatment options. CuraSen is... Read More
